You are currently viewing Surveillance for enteric fever in Asia project (SEAP) Phase III

Surveillance for enteric fever in Asia project (SEAP) Phase III

Project Summary

The Surveillance of Enteric Fever in Asia Project (SEAP) phase III is a prospective study multi site aiming to generate data to inform policy recommendations on enteric fever prevention and control, as well as facilitate typhoid vaccine implementation.

This study will address some shortcomings of previous studies and fill knowledge gaps regarding enteric fever in Asia through collection and synthesis of existing and prospective information. SEAP Phase II overall objectives are to characterize the burden of enteric fever in Nepal, including clinical manifestations, severity of illness, long-term sequelae of illness, antimicrobial resistance patterns of enteric fever isolates, evaluate new diagnostics, and cost of illness. This study will generate baseline data to inform appropriate interventions and facilitate the assessment of the impact of interventions while also characterizing risk factors for development of severe illness among enteric fever cases. This study currently collects data by combining hospital-based inpatient and outpatient surveillance and laboratory surveillance with a healthcare utilization survey to estimate disease burden for enteric fever. SEAP Phase II also include long-term follow-up of all blood culture confirmed cases to assess rates of relapse, mortality, and morbidity, and an economic evaluation to characterize the economic burden of enteric fever in Nepal.

The surveillance component of SEAP will also form the platform for an assessment of other causes of undifferentiated fever, including but not limited to rickettsia and leptospirosis.

Study Duration

From 11/01/2019 – 09/30/2022

Objectives

The objective of SEAP Phase III is to characterize the burden of enteric fever in Nepal, including clinical manifestations, severity of illness, long-term sequelae of illness, antimicrobial resistance patterns of enteric fever isolates, evaluate new diagnostics, and the cost of illness.

Outcomes

We continue to observe a high burden of typhoid in the SEAP study sites. Ongoing surveillance provides insights into the burden of disease in three countries at different TCV introduction stages. Continued data collection before, during, and after TCV introduction holds promise to inform further next steps, such as the need for better access to vaccination and the impact of vaccination on antimicrobial resistance. We also sequence the isolated salmonella isolates for the study of geospatial distribution. Case count was decrease in the early stages of the COVID-19 pandemic and remained low throughout the study period.

Team Members

Principal Investigator: Dr. Dipesh Tamrakar, Prof.  Dr Jason Andrews

Co-Investigator(s):: Dr. Rajeev Shrestha, Dr. Sailesh Pradhan, Dr. Nirajan Bhusal, Dr. Jyotshana Shrestha

Project Coordinator(s): Ms. Krista Vaidya, Mr. Shiva Ram Naga

Research Assistant(s): Mr. Sabin Bikram Shahi, Ms. Aarjya Tara Bajrachrya, Mr. Sudan Maharjan, Ms. Neeru Shrestha, Ms. Melina Thapa, Mr. Suraj Jakibanjar, Ms. Nisha Ale

Supported by: Sabin Vaccine Institute, USA

Collaborating Partner: Stanford University, San Francisco, USA

Publications

1. Munira SJ, Naga SR, Dehraj IF, Doyle K, Kanon N, Yousafzai MT, et al. Changes in enteric fever trends during the COVID-19 pandemic from the Surveillance for Enteric Fever in Asia Project: a cross-sectional study. The Lancet Regional Health – Southeast Asia. 2025 Apr;35:100562.

https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(25)00033-2/fulltext.